Arch Oncology, Inc

Annexon, Inc. is a biotechnology company based in Brisbane, CA, focused on developing next-generation therapies targeting complement-driven diseases of the body, brain, and eye. Founded by Dr. Ben Barres, a distinguished neuroscientist, the company aims to halt the damaging effects of the classical complement pathway, which plays a critical role in various autoimmunes and neurodegenerative disorders. With a strong emphasis on scientific innovation, Annexon is dedicated to delivering transformative therapies to patients suffering from these debilitating conditions. The company’s ongoing research and development efforts are geared towards advancing its pipeline of early complement inhibitors, aiming to provide effective treatment options for conditions such as dry age-related macular degeneration and more. Generated from the website

Pionyr Immunotherapeutics, Inc., a biotechnology company based in South San Francisco, CA, was acquired by Ikena Oncology, Inc. in August 2023. Their innovative Myeloid Tuning programs aim to enhance the immune system's anti-tumor response by modifying the cellular infiltrate of the tumor microenvironment. With clinical programs targeting TREM2 and TREM1, Pionyr focuses on selectively depleting and reprogramming tumor-associated macrophages responsible for immunosuppression, demonstrating safety in Phase 1a b trials alone and in combination with pembrolizumab. Additionally, their IND-ready program, PY265 anti-MARCO, aims to activate the immune system in the tumor microenvironment. Pionyr Immunotherapeutics has made significant contributions to the field of immunotherapy, as evidenced by their posters, publications, and whitepapers. As part of Ikena Oncology, the company's business development team is open to discussions regarding licensing and partnerships for their pioneering programs. With a commitment to advancing cancer treatment, Pionyr Immunotherapeutics continues to make strides in developing novel therapies to combat tumors and improve patient outcomes.Generated from the website

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, CA, dedicated to advancing treatments for patients suffering from inflammatory and immunologic diseases. The company's innovative approach focuses on developing therapeutics that intelligently target key drivers of the immune system to transform treatment outcomes and enhance the quality of life for countless individuals. With a commitment to addressing conditions such as food allergies and other allergic diseases, RAPT Therapeutics is at the forefront of scientific research and development. The company aims to empower patients through cutting-edge therapies, exemplified by their long-acting anti-IgE antibody, RPT904, which is designed to make a significant difference in the lives of those affected. Generated from the website